Generics Liability Bill Could Face Uphill Road In Senate
This article was originally published in The Pink Sheet Daily
Sen. Leahy plans to introduce legislation to overturn the Supreme Court’s ruling in Pliva v. Mensing; the attorney who represented generic manufacturers in that case says the legislation is unlikely to pass.
You may also be interested in...
Design defect claims made against generic companies are focus of a case involving Mutual Pharmaceutical’s generic sulindac; ruling may eliminate lower court carve-outs to its Mensing decision.
Jerry Avorn and his colleagues suggest that a new database be created at FDA to be managed by the agency’s Sentinel program, PCORI or another organization; they also recommend development of a “consensus label” and a minimum Rx fee to fund pharmacovigilance.
Personal injury firms began looking for clients after FDA announced that Impax/Teva’s generic product was not equivalent to GSK’s Wellbutrin XL, but Supreme Court’s Mensing decision may keep cases from getting off the ground.